For decades, medical professionals viewed subcutaneous fat primarily as a nuisance to be removed or a simple filler used to restore volume in aesthetic procedures. However, a significant shift in España innovación medicina regenerativa is redefining the biological utility of adipose tissue, transforming it from a passive filler into an active therapeutic agent.
Dr. Nabil Fakih-Gomez, a maxillofacial surgeon and the incoming president of the Sociedad Española de Cirugía Plástica Facial (SECPF), has developed a biological structure known as the fat membrane (or nanofat membrane). This innovation utilizes a patient’s own fat and blood to create a suturable, dense membrane capable of accelerating the healing of complex wounds and regenerating damaged tissues.
The technique represents a move toward “autologous biomaterials,” meaning the treatment is derived entirely from the patient. By eliminating the need for synthetic grafts or donor tissues, the procedure removes the risk of immunological rejection or the transmission of diseases, offering a streamlined approach to reconstructive and regenerative surgery.
The science of the biological scaffold
The production of the fat membrane relies on the synergy between two primary biological components: nanograsa (nanofat) and platelet-rich fibrin (PRF). The process begins with the mechanical emulsion of the patient’s subcutaneous fat, breaking it down into a nanofat rich in adipose-derived stem cells (ADSCs). Here’s then combined with PRF, a blood fraction that allows for the controlled release of growth factors.
Once mixed, these elements form a dense, adaptable membrane that surgeons can suture directly onto damaged areas or delicate surgical structures. Rather than acting as a simple cover, the membrane serves as a biological scaffold. It provides the physical structure necessary for cells to migrate and organize, while simultaneously releasing the chemical signals required for tissue repair.
Immunohistochemical analysis has confirmed that these membranes are biologically active. Research identified the presence of endothelial cells—specifically markers CD31, CD34, and ERG—which are critical for neovascularization. This means the membrane actively promotes the creation of new blood vessels, ensuring that the healing tissue receives the oxygen and nutrients necessary for recovery.
Clinical validation and patient outcomes
The application of this technology has moved beyond the conceptual stage into documented clinical practice. Between 2019 and 2024, a clinical team led by Dr. Fakih-Gomez treated 172 patients using fat membranes to address a variety of complex medical challenges.
The patient cohort included individuals suffering from chronic diabetic ulcers, skin necrosis following the injection of dermal fillers, postoperative complications, and facial scarring. In several instances, wounds that had remained open for months showed complete closure within a few weeks or months of the membrane application.
The clinical data indicated a notable improvement in recovery times with no reported complications. The efficiency of the process is also a key factor; the entire preparation of the membrane is completed in less than one hour, reducing the time the patient spends under anesthesia and eliminating the need for expensive complementary dressings.
Standardizing regenerative therapy
A primary challenge in regenerative medicine is the ability to reproduce results consistently across different patients, and practitioners. To solve this, Dr. Fakih developed the Fakih-Manay Fat Membrane Device, a specialized tool designed to standardize the production of the membrane.
This device allows surgeons to create membranes of precise sizes and thicknesses, tailored specifically to the dimensions of the patient’s wound. The system has been patented in the United States, signaling international recognition of the technique’s reproducibility and technical viability.
This advancement places the fat membrane in what experts describe as a “third generation” of autologous biomaterials. While first-generation materials were largely structural and second-generation materials added basic biological signals, this third generation combines cellular activity, growth factor release, and structural adaptability in a single, patient-specific device.
| Feature | Traditional Grafts/Fillers | Fat Membrane (Autologous) |
|---|---|---|
| Source | Synthetic or Donor | Patient’s own fat and blood |
| Rejection Risk | Possible | Negligible |
| Primary Function | Volume/Filling | Tissue Regeneration/Healing |
| Preparation Time | Variable | Under 60 minutes |
Impact on the future of surgical reconstruction
The implications of this Spanish innovation extend beyond aesthetic surgery. By providing an effective solution for chronic wounds, such as diabetic ulcers, the technique addresses a significant public health burden. Chronic wounds often lead to systemic infections and, in severe cases, amputation; a faster, autologous healing mechanism could significantly improve the quality of life for these patients.
The SECPF has expressed strong support for the dissemination of this research, noting that such advancements solidify Spain’s position as a global leader in advanced surgical research and biomedical innovation.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a board-certified physician to determine if regenerative therapies are appropriate for their specific medical condition.
As the medical community continues to evaluate the long-term outcomes of the 172-patient study, the next phase of development will likely focus on expanding the indications for the fat membrane in other areas of reconstructive surgery. Further clinical trials and peer-reviewed publications are expected to refine the protocols for widespread international adoption.
Do you have questions about the future of regenerative medicine? Share this article and join the conversation in the comments below.
